EC approves Takeda’s $62bn acquisition of Shire
The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap
The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap
Through the acquisition of Avista, Cambrex will be adding early stage small molecule development and testing services to its capabilities. Avista, which is a portfolio company of Ampersand
LEO Pharma research vice president Thorsten Thormann said: “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin
This decision vacates the District Court’s preliminary injunction that had prohibited Dr. Reddy’s from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result
The approval for Gamifant is for paediatric, both new born and older, and adult HLH patients whose condition is refractory, recurrent or progressive or are intolerant to conventional
In the trail, the clinical-stage biotechnology company will evaluate uproleselan in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and idarubicin). Both
The submission is supported by a paediatric open-label study conducted in children aged six to 11 years that investigated pharmacokinetics, pharmacodynamics and long-term safety. Mepolizumab, a humanised anti-IL5
This recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Bristol-Myers Squibb melanoma and genitourinary
One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from
The FDA designation for the Tecentriq chemo combination is for TNBC patients whose condition is unresectable locally advanced or metastatic and whose disease expresses the PD-L1 protein, as